What does Farmadistri do?

Farmadistri is a wholesaler in Oudenburg. Private Limited, started on 21 December 2018, 1 establishment.

What is the address of Farmadistri?

The registered office of Farmadistri is located at Brugsesteenweg 5A, 8460 Oudenburg.

Is Farmadistri still active?

Yes. According to the CBE (29 October 2026) Farmadistri is active, legal situation “Normale toestand”, started on 21 December 2018.

Is Farmadistri registered on Peppol?

Yes, Farmadistri is registered on the Peppol network with ID 0208:0716742995.

What is the enterprise number of Farmadistri?

The enterprise number of Farmadistri is BE0716742995.

When was Farmadistri founded?

Farmadistri was founded on 21 December 2018.

Is Farmadistri a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 2018; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did Farmadistri make in 2025?

Farmadistri posted a profit after taxes of € 479,926 in financial year 2025.

What is the revenue of Farmadistri?

As a small company, Farmadistri is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 701,238.

How much does an employee at Farmadistri earn?

The average wage cost per full-time employee at Farmadistri was € 46,000 in 2025: staff costs of € 96,658 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Farmadistri have?

According to the 2025 annual accounts, Farmadistri has 2.1 full-time equivalents (FTE).

Farmadistri (Private Limited) - Oudenburg - BE0716742995

Q: Who are the directors of Farmadistri?

According to the 2025 annual accounts, the directors of Farmadistri are: MEULEMEESTER STEVEN BV, VCP GP BV, BOBBIE PHARMACEUTICAL SERVICES BV, VYBROS CAPITAL PARTNERS BV.

Dossier Farmadistri, printed on 29 October 2026 from databakkes.be/en/0716742995/farmadistri. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Farmadistri from Oudenburg, company number BE0716742995, closed financial year 2025 with a result of € 479,926 after tax. For that financial year Farmadistri recorded a gross margin of € 701,238 and equity of € 759,871. Compared with financial year 2024, the result moved from € 408,590 to € 479,926. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Growing

€ 759,871

▲ 77% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 479,926

▲ 17% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 35,359

▲ € 31,772 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 150,000 paid out

31 % of the profit went to the shareholders, mostly to MEDIPACK (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.1

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 96,658

▼ 12% vs 2024

€ 46,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,567

Of which on lease € 17,567.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 37,110

▲ 144% vs 2024

€ 26,720 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 449,988

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 47,413

▼ 27% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 241,302 Gross margin 2022: € 241,302 First fiscal year in the series	€ 292,953 Gross margin 2023: € 292,953 ▲ 21% vs 2022 (€ 241,302) Favourable step	€ 629,847 Gross margin 2024: € 629,847 ▲ 115% vs 2023 (€ 292,953) Favourable step	€ 701,238 Gross margin 2025: € 701,238 ▲ 11% vs 2024 (€ 629,847) Favourable step	▲ 11%
Profit after taxes	€ 191,040 Profit after taxes 2022: € 191,040 First fiscal year in the series	€ 206,916 Profit after taxes 2023: € 206,916 ▲ 8% vs 2022 (€ 191,040) Favourable step	€ 408,590 Profit after taxes 2024: € 408,590 ▲ 97% vs 2023 (€ 206,916) Favourable step	€ 479,926 Profit after taxes 2025: € 479,926 ▲ 17% vs 2024 (€ 408,590) Favourable step	▲ 17%
Equity	€ 234,439 Equity 2022: € 234,439 First fiscal year in the series	€ 421,355 Equity 2023: € 421,355 ▲ 80% vs 2022 (€ 234,439) Favourable step	€ 429,945 Equity 2024: € 429,945 ▲ 2% vs 2023 (€ 421,355) Favourable step	€ 759,871 Equity 2025: € 759,871 ▲ 77% vs 2024 (€ 429,945) Favourable step	▲ 77%
Total debts	€ 331,386 Total debts 2022: € 331,386 First fiscal year in the series	€ 389,019 Total debts 2023: € 389,019 ▲ 17% vs 2022 (€ 331,386) Unfavourable step	€ 982,909 Total debts 2024: € 982,909 ▲ 153% vs 2023 (€ 389,019) Unfavourable step	€ 830,789 Total debts 2025: € 830,789 ▼ 15% vs 2024 (€ 982,909) Favourable step	▼ 15%
Cash	€ 245,258 Cash 2022: € 245,258 First fiscal year in the series	€ 180,695 Cash 2023: € 180,695 ▼ 26% vs 2022 (€ 245,258) Unfavourable step	€ 3,587 Cash 2024: € 3,587 ▼ 98% vs 2023 (€ 180,695) Unfavourable step	€ 35,359 Cash 2025: € 35,359 ▲ € 31,772 vs 2024 (€ 3,587) Favourable step	▲ € 31,772
Retained profit	€ 228,139 Retained profit 2022: € 228,139 First fiscal year in the series	€ 415,055 Retained profit 2023: € 415,055 ▲ 82% vs 2022 (€ 228,139) Favourable step	€ 423,645 Retained profit 2024: € 423,645 ▲ 2% vs 2023 (€ 415,055) Favourable step	€ 753,571 Retained profit 2025: € 753,571 ▲ 78% vs 2024 (€ 423,645) Favourable step	▲ 78%
Dividend	€ 40,000 Dividend 2022: € 40,000 First fiscal year in the series	€ 20,000 Dividend 2023: € 20,000 ▼ 50% vs 2022 (€ 40,000) Unchanged	€ 400,000 Dividend 2024: € 400,000 ▲ € 380,000 vs 2023 (€ 20,000) Unchanged	€ 150,000 Dividend 2025: € 150,000 ▼ 62% vs 2024 (€ 400,000) Unchanged	▼ 62%
Bank debt	€ 5,017 Bank debt 2022: € 5,017 First fiscal year in the series	€ 10,132 Bank debt 2023: € 10,132 ▲ 102% vs 2022 (€ 5,017) Unfavourable step	€ 15,216 Bank debt 2024: € 15,216 ▲ 50% vs 2023 (€ 10,132) Unfavourable step	€ 37,110 Bank debt 2025: € 37,110 ▲ 144% vs 2024 (€ 15,216) Unfavourable step	▲ 144%
Balance sheet total	€ 565,824 Balance sheet total 2022: € 565,824 First fiscal year in the series	€ 810,374 Balance sheet total 2023: € 810,374 ▲ 43% vs 2022 (€ 565,824) Unchanged	€ 1,412,854 Balance sheet total 2024: € 1,412,854 ▲ 74% vs 2023 (€ 810,374) Unchanged	€ 1,590,661 Balance sheet total 2025: € 1,590,661 ▲ 13% vs 2024 (€ 1,412,854) Unchanged	▲ 13%
Employees (FTE)	-	1 Employees (FTE) 2023: 1 First fiscal year in the series	2 Employees (FTE) 2024: 2 ▲ 1 vs 2023 (1) Unchanged	2.1 Employees (FTE) 2025: 2.1 ▲ 0.1 vs 2024 (2) Unchanged	▲ 0.1

Key figures of Farmadistri, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Farmadistri?

What happened at Farmadistri in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 14, 2026 New annual accounts for financial year 2025: profit of € 479,926 (▲ 17% vs 2024). Source: NBB ↗
Jan 2, 2019 New establishment in Oudenburg. KBO
Dec 21, 2018 Start of the company according to the CBE. KBO

In short

From € 191,040 profit in 2022 to € 479,926 profit in 2025.

Paid € 327,470 in corporate taxes since 2022.

Best year ever: 2025, with € 479,926 profit.

On average € 333,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MEDIPACK 100%

Bobbie Pharmaceutical Services 100%

The stake of MEDIPACK, Bobbie Pharmaceutical Services comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Farmadistri

Behind Farmadistri are MEULEMEESTER STEVEN BV, VCP GP BV, BOBBIE PHARMACEUTICAL SERVICES BV and VYBROS CAPITAL PARTNERS BV. The shares are held by MEDIPACK (100%) and Bobbie Pharmaceutical Services (100%).